Showing results (41-50 of 98) with videos related to

Sort By:
Pageof 10
Environmental Health Perspectives|August 31, 2000
Controlled human exposure to methyl tertiary butyl ether in gasoline: symptoms, psychophysiologic and neurobehavioral responses of self-reported sensitive personsN Fiedler, K Kelly-McNeil, S Mohr, et al.
Journal of Clinical Medicine|December 10, 2021
Lymphocytopenia and Anti-CD38 Directed Treatment Impact the Serological SARS-CoV-2 Response after Prime Boost Vaccination in Patients with Multiple MyelomaSusanne Ghandili, Martin Schönlein, Christian Wiessner, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 23, 2025
Ranking the Importance of Prognostic Factors for Relapsed/Refractory Multiple Myeloma: International Physician Panel Consensus Following a Systematic Literature ReviewShaji Kumar, Xavier Leleu, Katja C Weisel, et al.
Leukemia|April 25, 2020
Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myelomaHartmut Goldschmidt, Meletios A Dimopoulos, S Vincent Rajkumar, et al.
Leukemia & Lymphoma|August 3, 2018
Cereblon gene expression and correlation with clinical outcomes in patients with relapsed/refractory multiple myeloma treated with pomalidomide: an analysis of STRATUSXiaozhong Qian, Meletios A Dimopoulos, Michael Amatangelo, et al.
Hemasphere|July 17, 2025
Current and future role of carfilzomib-based quadruplet combinations as therapy for newly diagnosed multiple myelomaOla Landgren, Noa Biran, Elizabeth K O'Donnell, et al.
Leukemia & Lymphoma|February 10, 2010
A phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomasEckhart Weidmann, Georg Hess, Kai U Chow, et al.
The American Journal of Pathology|October 13, 2012
BDNF/TrkB signaling augments smooth muscle cell proliferation in pulmonary hypertensionGrazyna Kwapiszewska, Karolina Chwalek, Leigh M Marsh, et al.
Cancers|September 28, 2023
Daratumumab, Bortezomib, and Dexamethasone for Treatment of Patients with Relapsed or Refractory Multiple Myeloma and Severe Renal Impairment: Results from the Phase 2 GMMG-DANTE TrialLisa B Leypoldt, Maria Gavriatopoulou, Britta Besemer, et al.
Clinical and Translational Science|June 26, 2020
Early M-Protein Dynamics Predicts Progression-Free Survival in Patients With Relapsed/Refractory Multiple MyelomaXiaoyu Yan, Xu Steven Xu, Katja C Weisel, et al.
Pageof 10